Concurrent pembrolizumab and chemotherapy in classical Hodgkin lymphoma

Ryan Lynch, MD, Seattle Cancer Care Alliance, University of Washington, Seattle, WA, discusses concurrent pembrolizumab, an anti-PD⁠-⁠1 monoclonal antibody, with AVD (doxorubicin, vinblastine, and dacarbazine) in patients with classical Hodgkin lymphoma (cHL). The treatment regimen displayed promising efficacy and safety and in patients. However, the interim-positron emission tomography (PET) scan results did not align with the high progression-free survival rates observed, and cell-free DNA (cfDNA) may predict outcomes more accurately. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

• kategori